Latest News

A recent study reveals that patient-reported side effect bother significantly predicts early treatment discontinuation in cancer therapies, highlighting the importance of patient feedback.

Innovations in cancer immunotherapy highlight the urgent need for effective management of immune-related toxicities, emphasizing precision medicine and interdisciplinary collaboration.

A recent study reveals that medication burden significantly increases acute care use in older metastatic prostate cancer patients on androgen receptor inhibitors.

Izalontamab shows promise as a safe treatment for advanced epithelial tumors, demonstrating early antitumor activity in a recent clinical trial.

A study reveals that lower KIM-1 levels predict better outcomes in advanced renal cell carcinoma patients treated with nivolumab and ipilimumab.

New trial results reveal sacituzumab govitecan shows promise for HR+/HER2– metastatic breast cancer, despite missing primary survival goals.

Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients.

New research identifies CD8+ PD-1+ TIM-3- LAG-3 TILs as promising biomarkers for improved outcomes in metastatic clear cell renal cell carcinoma treatments.

The DISCUS trial reveals that shorter systemic therapy improves quality of life for advanced urothelial cancer patients, challenging traditional treatment durations.

The FDA has approved daratumumab and hyaluronidase for the treatment of patients with high-risk smoldering multiple myeloma.

Nivolumab combined with visugromab demonstrates enhanced efficacy and tolerability in treating muscle-invasive bladder cancer, outperforming placebo in a recent trial.

A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.

The FDA designates M2T-CD33 as an orphan drug, highlighting its potential as a safer, innovative treatment for acute myeloid leukemia.

The EDGE-Gastric trial reveals promising results for domvanalimab and zimberelimab in treating advanced gastric cancer, showcasing durable efficacy and manageable safety.

During a live event, Lori Wirth, MD, discussed preferred treatment for thyroid cancer with and without a RET, NTRK, or ALK fusion.

During a live event, Wade T. Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage small cell lung cancer.

Neoadjuvant gemcitabine plus cetrelimab shows promising pCR and RFS rates in muscle-invasive bladder cancer, highlighting new treatment options.

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

A novel combination therapy shows promise for preserving kidneys in high-risk upper tract urothelial carcinoma, challenging traditional treatment methods.

Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors.

New data reveals lifileucel shows promising efficacy and safety in treating advanced non-small cell lung cancer, paving the way for potential FDA approval.

Camizestrant shows promising antitumor activity and tolerability when combined with CDK4/6 inhibitors in patients with advanced ER+, HER2– breast cancer.

Bexmarilimab combined with azacitidine shows promising efficacy and safety in patients with high-risk myelodysplastic syndrome, paving the way for new treatment options.

During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.

Sevabertinib demonstrates promising safety and efficacy in treating non-small cell lung cancer with HER2 or EGFR mutations, offering hope for patients.

Vorasidenib shows significant long-term benefits for IDH-mutant glioma patients, enhancing survival and delaying treatment needs post-surgery.

Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing hospital stays for patients with blood cancers.

Whole-genome sequencing uncovers critical genomic insights in salivary gland cancer, paving the way for targeted therapies and improved patient outcomes.

New research reveals that CD26+ leukemia stem cell levels at diagnosis predict treatment response in chronic myeloid leukemia patients, enhancing TKI therapy strategies.